利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

502 条记录 (耗时 0.026 秒)

    GLUTATHIONE DERIVATIVE
    91.
    发明公开
    GLUTATHIONE DERIVATIVE 失效
    谷胱甘肽衍生物

    公开(公告)号：EP0469156A1

    公开(公告)日：1992-02-05

    申请号：EP91904331.5

    申请日：1991-02-15

    申请人： Senju Pharmaceutical Co., Ltd.

    发明人： OHMORI, Shinji ,  OGATA, Kazumi ,  SAKAUE, Takahiro

    IPC分类号： C07K5/02 ,  C07K1/02 ,  A61K38/06

    CPC分类号： C07K5/0215 ,  A61K38/00

    摘要： Anti-inflammatory, antiallergic or hepatopathy inhibitor contain ing the compound of general formula (I), or a pharmacologically acceptable salt thereof as the active ingredient, wherein n is 0 or 1, R 1 represents hydrogen or alkyl, and R 2 and R 3 may be the same or different from each other and each represents hydroxyl, lower alkoxy, amino or imino, provided that R 1 represents alkyl when n is 0 and R 2 and R 3 , which may be the same or different from each other, represent each hydroxyl or lower alkoxy.

    摘要翻译： 包含通式（I）的化合物或其药理学上可接受的盐作为活性成分的抗炎，抗过敏或肝病抑制剂，其中n是0或1，R 1表示氢或烷基，并且R 2和R 3可以是 相同或不同，并且各自代表羟基，低级烷氧基，氨基或亚氨基，条件是当n是0时，R 1代表烷基，并且R 2和R 3可以彼此相同或不同，代表每个羟基或低级烷氧基。

    Pharmaceutical compositions for inhibition of maillard's reaction
    92.
    发明公开
    Pharmaceutical compositions for inhibition of maillard's reaction 失效
    Pharmazeutische Zusammensetzungen zur Hemmung der Maillardreaktion。

    公开(公告)号：EP0433679A2

    公开(公告)日：1991-06-26

    申请号：EP90122096.2

    申请日：1990-11-19

    申请人： Senju Pharmaceutical Co., Ltd.

    发明人： Inoue, Jun

    IPC分类号： A61K31/535 ,  A61K31/47

    CPC分类号： A61K31/47 ,  A61K31/535

    摘要： Presented are pharmaceutical compositions comprising in admixture with a carrier a compound of;

    (a) the formula (I) or a pharmaceutically acceptable salt thereof:
    wherein R₁ and R₂ are each hydrogen, methyl, trifluoromethyl, carboxy, methoxycarbonyl or ethoxycarbonyl, and R₃ is hydrogen or hydroxy;
    (b) the formula (I) or a pharmaceutically acceptable salt thereof:
    wherein R, R₂ and R₃ are as defined;
    (c) the formula (III) or a pharmaceutically acceptable salt thereof:
    wherein R₄ and R₅ are each hydrogen or form, by incorporation of C₁ and C₂ carbon atoms, a condensed [2.1-b] pyridine ring optionally substituted with a hydroxyl group or a carboxyl group, and R₆ is hydrogen or hydroxy; or
    (d) the formula (IV) or a pharmaceutically acceptable salt thereof:
    wherein R₄, R₅ and R₆ are as defined.

    The compositions are used to inhibit Maillard's reaction in human body, the reaction which may be responsible for the development of diabetic complications and age-associated disorders. Methods of treatment and prophylaxis of such complications and disorders are also presented.

    摘要翻译： 提供的是药物组合物，其包含与载体的混合物， （a）式（I）或其药学上可接受的盐：其中R 1和R 2各自为氢，甲基，三氟甲基，羧基，甲氧基羰基或乙氧基羰基，R 3为氢或羟基; （b）式（I）或其药学上可接受的盐：其中R，R 2和R 3如所定义; （c）式（III）或其药学上可接受的盐：其中R 4和R 5各自为氢或通过并入C1和C2的碳原子形成稠合的[2.1-b]吡啶环，其任选地被 羟基或羧基，R6是氢或羟基; 或（d）式（IV）或其药学上可接受的盐：其中R 4，R 5和R 6如上所定义。 该组合物用于抑制美拉德在人体中的反应，这可能是糖尿病并发症和年龄相关疾病发展的反应。 还提出了治疗和预防这些并发症和病症的方法。

    Dental plaque inhibitor
    93.
    发明公开
    Dental plaque inhibitor 失效
    Mittel zur Verhinderung von Zahnbelagbildung。

    公开(公告)号：EP0376162A2

    公开(公告)日：1990-07-04

    申请号：EP89123675.4

    申请日：1989-12-21

    申请人： Senju Pharmaceutical Co., Ltd.

    发明人： Morisaki, Mayumi

    IPC分类号： A61K6/00 ,  A61K7/16

    CPC分类号： A61K8/55 ,  A61K8/0216 ,  A61K8/678 ,  A61K2800/222 ,  A61Q11/00

    摘要： Provided are dental plaque inhibitor compositions com­prising a compound of the formula:
    wherein R₁, R₂ and R₃ are the same or different and each is a hydrogen atom or a methyl group or a pharmaceutically ac­ceptable salt thereof.
    The compositions inhibit the formation of dental plaque by inhibiting the transformation of sucrose into insoluble polysaccharides.

    摘要翻译： 提供的牙斑抑制剂组合物包含下式化合物：其中R 1，R 2和R 3相同或不同，并且各自为氢原子或甲基或其药学上可接受的盐。 该组合物通过抑制蔗糖转化为不溶性多糖来抑制牙斑的形成。

    Mixed phosphoric diesters, preparation thereof, and use thereof as antiinflammatory agents
    95.
    发明公开
    Mixed phosphoric diesters, preparation thereof, and use thereof as antiinflammatory agents 失效
    混合磷酸钙，其制备方法及其作为抗炎剂的用途

    公开(公告)号：EP0236120A3

    公开(公告)日：1989-10-11

    申请号：EP87301842.8

    申请日：1987-03-03

    申请人： Senju Seiyaku Kabushiki Kaisha also known as Senju Pharmaceutical Co. Ltd.

    发明人： Yamamoto, Itaru ,  Ogata, Kazumi

    IPC分类号： C07F9/12 ,  A61K31/665

    CPC分类号： A61K31/665 ,  C07F9/65586 ,  Y02P20/55

    摘要： Phosphoric diesters of general formula:
    [wherein R₁ and R₂ are the same or different and each means a methyl group or a hydrogen atom, provided that at least one of R₁ and R₂ is a hydrogen atom, or a salt thereof] can be produced by reacting β, γ or δ-tocopherol with a halophosphorylating agent such as phosphorus oxychloride, reacting the resultant product with ascorbic acid whereof hydroxyl groups at 5- and 6-­positions are protected, and then removing protected groups from the hydroxy groups. The phosphoric diesters are novel compounds having antiinflammatory activity.

    摘要翻译： 磷酸二酯：... ... [其中R1和R2相同或不同，各自表示甲基或氢原子，条件是R 1和R 2中的至少一个为氢原子，或其盐 ]可以通过使β，γ或δ-生育酚与卤代磷酰化剂如磷酰氯反应，使所得产物与抗坏血酸反应，其中5-和6-位的羟基被保护，然后从羟基上除去保护基团 组。 磷酸二酯是具有抗炎活性的新型化合物。

    1-Hydroxy-5-oxo-5H-pyrido(3,2-a)-phenoxazine-3-carboxylic acid esters
    96.
    发明公开
    1-Hydroxy-5-oxo-5H-pyrido(3,2-a)-phenoxazine-3-carboxylic acid esters 失效
    1-羟基-5-氧代-5H-吡啶并[3,2-α〕-phenoxazin -3-carbonsäureester。

    公开(公告)号：EP0254167A1

    公开(公告)日：1988-01-27

    申请号：EP87110051.7

    申请日：1987-07-11

    申请人： Senju Pharmaceutical Co., Ltd.

    发明人： Terayama, Hideo ,  Inoue, Jun

    IPC分类号： C07D498/04 ,  A61K31/535 ,  A61K31/435

    CPC分类号： C07D498/04

    摘要： The compounds represented by the general formula
    wherein R is an alkyl group having 1-10 carbon atoms are novel compounds which have not been reported in the literature. Since they have excellent affinities for tissues with particular high corneal permeability and show anticataract activity at low concentration, the compounds are of value as prophylactic and therapeutic agents for cataract.

    摘要翻译： 由通式表示的化合物，其中R是具有1-10个碳原子的烷基是新的化合物，其在文献中没有报道。 由于它们对于具有特别高的角膜通透性的组织具有优异的亲和力，并且在低浓度下显示出抗龋齿活性，因此该化合物作为白内障的预防和治疗剂是有价值的。